Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 10, 2014, Pages 1997-2008

  Joura, Elmar A ^a   Ault, Kevin A ^b   Bosch, F Xavier ^c   Brown, Darron ^d   Cuzick, Jack ^e   Ferris, Daron ^f   Garland, Suzanne M ^g   Giuliano, Anna R ^h   Hernandez Avila, Mauricio ⁱ   Huh, Warner ^j   Iversen, Ole Erik ^k   Kjaer, Susanne K ^l,m   Luna, Joaquin ⁿ   Miller, Dianne ^o   Monsonego, Joseph ^p   Munoz, Nubia ^q   Myers, Evan ^r   Paavonen, Jorma ^s   Pitisuttithum, Punnee ^t   Steben, Marc ^u   Wheeler, Cosette M ^v,w   Perez, Gonzalo ^x,y   Saah, Alfred ^x   Luxembourg, Alain ^x   Sings, Heather L ^x   Velicer, Christine ^x   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^j University of Alabama   (United States)

^k UNIVERSITY OF BERGEN   (Norway)

^l DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^m UNIVERSITY OF COPENHAGEN   (Denmark)

ⁿ Instituto de Investigaciones   (Colombia)

^o UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^p Institut du Col   (France)

^q Instituto Nacional de Cancerología   (Colombia)

^r DUKE UNIVERSITY MEDICAL CENTER   (United States)

^s HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^t MAHIDOL UNIVERSITY   (Thailand)

^u INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^v UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^w UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^x MERCK RESEARCH LABORATORIES   (United States)

^y UNIVERSIDAD DEL ROSARIO   (Colombia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADENOCARCINOMA; ADOLESCENT; ADULT; ALGORITHM; ALPHAPAPILLOMAVIRUS; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GENOTYPE; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MIXED INFECTION; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PHASE 3 CLINICAL TRIAL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; CERVICAL INTRAEPITHELIAL NEOPLASIA; GENETICS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTOR; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; INCIDENCE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84907516546     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0410     Document Type: Article

References (34)

1. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
2. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
3. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45.
4. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007;369:1693-702.
5. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364: 401-11.
6. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New Engl J Med 2011;365:1576-85.
7. Munoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial. Lancet 2009; 373:1949-57.
8. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208:385-93.
9. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012;206:1645-51.
10. Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;348:g1458.
11. Powell SE, Hariri S, Steinau M, Bauer HM, BennettNM, Bloch KC, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012; 31:109-13.
12. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032.
13. GertigDM, Brotherton JM, Budd AC, DrennanK, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11: 227.
14. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012;102:833-5.
15. Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, Gaydos JC. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine.MSMR 2013;20:17-20.
16. Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparen P, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012;206:860-6.
17. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013;40: 130-5.
18. Baldur-Felskov B, Dehlendorff C, munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014;106:dit460. DOI10.1093/jnci/dit460. Epub 2014 Feb 2.
19. IARC monographs on the evaluation of carcinogenic risks to humans: Vol 100 B, a review of human carcinogens. Part B: biological agents. [Internet] Lyon, France: International Agency for Research on Cancer; 2012 [cited 2013 Nov 22]. Available from: http://monographs.iarc.fr/ ENG/Monographs/vol100B/mono100B-1.pdf.
20. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012;7:38.
21. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17: 1611-22.
22. International patent numbers WO 2003/019143 A2, WO 2006/116276 A2, and WO 2006/116303 A2. [Internet] 2008 [cited 2011 Feb 21]. Available from: http://patentscope.wipo.int/search/en/result.jsf.
23. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
24. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
25. Sahasrabuddhe VV, Castle PE, Follansbee S, Borgonovo S, Tokugawa D, Schwartz LM, et al. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. J Infect Dis 2013;207:392-401.
26. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011;20:287-96.
27. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009;125:2151-8.
28. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
29. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
30. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer 2009;45:2632-9.
31. The American Congress of Obstetricians and Gynecologists. New cervical cancer screening recommendations from the U.S. Preventive Services Task Force and the American Cancer Society/American Society for Colposcopy and Cervical Pathology/American Society for Clinical Pathology. [Internet] Washington, DC, [updated 2012 Mar 14; cited 2014 Jan13]. Available from: https://provider.carefirst. com/wcmresources/Content-Provider/assets/attachments/ACOG-Cervical-Cancer-Screening.pdf.
32. Roche [Internet] Switzerland: FDA Advisory committee unanimously recommends Roche's HPV test as primary screening tool for detection of women at high risk for cervical cancer. [updated 2014 Mar 13; cited 2014 Mar 27]. Available from: http://www.roche.com/media/media-releases/med-cor-2014-03-13.htm.
33. Merck [Internet] Whitehouse Station, NJ: Merck's investigational 9-valent HPV vaccine, V503, prevented 97 percent of cervical, vaginal and vulvar pre-cancers caused by five additional HPV types, in phase III study. [updated 2013 Nov 4; cited 18 Jun 2014]. Available from: http://www.mercknewsroom.com/news-release/research-and-development-news/mercks-investigational-9-valent-hpv-vaccine-v503-prevente.
34. Centers for Disease Control and Prevention [Internet] Atlant, GA: HPV vaccine: safe, effective, and grossly underutilized. [updated 2013 Jul 26; cited 2013 Aug 14]. Available from: http://www.cdc.gov/media/ releases/2013/p0725-HPV-vaccine.html.